TrialA Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency
Trial details
- Registry ID
- NCT02476916
- Phase
- Phase 2
Drug research
AG-348
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Mitapivat
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyNCT02476916 | AGIO | Phase 2 | Completed | 2017-05-08Actual |
| A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaNCT03692052 | AGIO | Phase 2 | Active not recruiting | 2020-08-20Actual |
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
Trial details
- Registry ID
- NCT03692052
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |